接受Olaparib 治療的晚期前列腺癌患者罹患肺孢子菌肺炎

  李宗霖、邵翊紘、黃亮鋼、甘弘成、林柏宏、虞凱傑、吳俊德、莊正鏗、馮思中

林口長庚紀念醫院泌尿科

 Pneumocystis Pneumonia in a Patient with Advanced Prostate Cancer Receiving Olaparib Therapy

  Chung-Lin Lee,I-Hung Shao,  Liang-Kang Huang, Hung-Chen Kan, Chung-Yi Liu, Po-Hung Lin, Kai-Jie Yu, Chun-Te Wu, Cheng-Keng Chuang^,, See-Tong Pang

 Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taiwan

  Abstract

We present a case of pneumocystis pneumonia (PCP) in a 79-year-old male diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who was undergoing treatment with olaparib. Following two relapses of mCRPC, olaparib was initiated as maintenance therapy after completing Lu 177 therapy. The patient had no underlying immunodeficiency issues and tested negative for HIV. Subsequently, the patient required ICU admission and intubation for management. Shortly after starting olaparib, the patient exhibited symptoms of fever and fatigue. Subsequent laboratory tests and imaging confirmed the diagnosis of PCP. Treatment with corticosteroids, trimethoprim/sulfamethoxazole, and later atovaquone led to significant improvement in the patient's overall condition. The observed lymphocytopenia post-olaparib administration might have contributed to the development of PCP.